Multiplatform
AI Ecosystem
for Drug Discovery
Our AI-driven platforms help discovery teams navigate structural uncertainty, optimization trade-offs, and complex design challenges from hit discovery to lead optimization.
Biology determines the strategy.
The multiplatfrom ecosystem delivers an objective, modality-agnostic therapeutic solution.
.avif)
Small Molecules Platform
- AI drug discovery workflows for different target classes: kinases, GPCRs, ion channels, enzymes, etc.
- AI pocket identification and targeting including allosteric, hidden, transient, and cryptic pockets.
- Automated SAR analysis with a hybrid intelligence approach; AI binding mode identification.
- Multiparametric virtual screening and lead optimization with QuorumMap.
- Selectivity optimization against highly similar isoforms and mutants.
- The largest set of ADMET endpoints for prediction and optimization with ADMETiQ.
Peptide Platform
- De novo binder design based on endogenous ligands, PPI partners, or display hits.
- Library of 10K+ non-canonical amino acids, non-peptide blocks, and linkage chemistry for unlimited diversity.
- Multiparametric optimization of peptide activity, permeability, and oral availability.
- Peptide-to-small-molecule workflow to develop compounds with superior ADMET properties.
- Scaffold-agnostic system that supports peptides of any topology and secondary structure.
Proximity Inducers Platform
- Designing various proximity inducers, such as degraders and molecular glues and PPI disruptors.
- Enabling antibody-based therapeutics, including bispecifics, immune cell engagers, and antibody-guided scaffolds.
- Predicting PPI structures and ternary complexes without known structures and homology templates.
- Targeting both natural and induced PPIs, including transient and membrane interactions.
- Developing diverse modalities such as small molecules, peptides, antibody-derived formats, or drug conjugates.
.avif)
